ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Reaffirmed by Truist Financial

ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “hold” rating reissued by stock analysts at Truist Financial in a research note issued on Wednesday, MarketBeat reports. They currently have a $60.00 price objective on the specialty pharmaceutical company’s stock, down from their prior price objective of $80.00. Truist Financial’s target price points to a potential upside of 6.86% from the company’s previous close.

Several other research analysts have also commented on the stock. StockNews.com lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. HC Wainwright restated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.75.

ANI Pharmaceuticals Stock Up 3.4 %

Shares of ANI Pharmaceuticals stock opened at $56.15 on Wednesday. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. The business has a 50-day moving average price of $61.45 and a 200 day moving average price of $63.89. ANI Pharmaceuticals has a fifty-two week low of $48.20 and a fifty-two week high of $70.81. The firm has a market cap of $1.18 billion, a P/E ratio of 35.09 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The business had revenue of $138.00 million during the quarter, compared to the consensus estimate of $129.09 million. During the same period in the previous year, the business earned $1.06 EPS. The business’s quarterly revenue was up 18.5% on a year-over-year basis. On average, sell-side analysts forecast that ANI Pharmaceuticals will post 3.5 earnings per share for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 11,000 shares of the company’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $63.38, for a total value of $697,180.00. Following the completion of the transaction, the chief operating officer now owns 671,620 shares in the company, valued at approximately $42,567,275.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the transaction, the senior vice president now directly owns 193,226 shares of the company’s stock, valued at $12,258,257.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Muthusamy Shanmugam sold 11,000 shares of the company’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $63.38, for a total transaction of $697,180.00. Following the completion of the sale, the chief operating officer now directly owns 671,620 shares of the company’s stock, valued at approximately $42,567,275.60. The disclosure for this sale can be found here. Insiders have sold a total of 65,757 shares of company stock worth $4,075,585 in the last ninety days. 12.70% of the stock is owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several large investors have recently bought and sold shares of ANIP. Rubric Capital Management LP increased its stake in shares of ANI Pharmaceuticals by 32.8% during the fourth quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock valued at $62,032,000 after acquiring an additional 277,989 shares during the period. Millennium Management LLC raised its stake in shares of ANI Pharmaceuticals by 1,005.8% in the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock worth $14,651,000 after buying an additional 209,272 shares in the last quarter. Global Alpha Capital Management Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 10.8% in the fourth quarter. Global Alpha Capital Management Ltd. now owns 582,428 shares of the specialty pharmaceutical company’s stock valued at $32,115,000 after buying an additional 56,900 shares during the period. American Century Companies Inc. boosted its stake in ANI Pharmaceuticals by 99.2% during the second quarter. American Century Companies Inc. now owns 99,831 shares of the specialty pharmaceutical company’s stock valued at $6,357,000 after buying an additional 49,717 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in ANI Pharmaceuticals by 121.3% during the first quarter. Assenagon Asset Management S.A. now owns 83,944 shares of the specialty pharmaceutical company’s stock worth $5,803,000 after acquiring an additional 46,008 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.